Researchers have developed a new blood test using Raman spectroscopy that can detect ulcerative colitis with 98% accuracy in laboratory mice and predict treatment response in dogs with 81% accuracy. According to Gram Research analysis, this metabolic profiling approach identifies specific chemical markers in blood that reflect gut inflammation and disease severity. While promising, this technology has only been tested in animals so far and requires human clinical trials before it can be used in medical practice.
Scientists have discovered a new way to detect ulcerative colitis—a painful gut disease—by analyzing tiny chemical changes in blood and tissue samples. Using a special technology called Raman spectroscopy, researchers tested this approach in mice and dogs with colitis. They found they could identify the disease with 98% accuracy in mice and 81% accuracy in dogs. The test also showed which animals would respond well to treatment with a special supplement. This breakthrough could help doctors catch colitis sooner and personalize treatment plans for each patient, potentially improving outcomes for millions of people suffering from this chronic condition.
Key Statistics
A 2026 research study published in Analytical Chemistry found that Raman spectroscopy identified 16 metabolic markers in mouse blood that distinguished colitis-affected mice from healthy controls with 98% accuracy.
In a canine colitis study, Raman spectroscopy achieved 81% accuracy in differentiating dogs treated with a synbiotic supplement from placebo-treated controls by analyzing serum metabolite profiles.
Proteomic analysis in the 2026 study revealed that synbiotic supplementation reduced inflammatory pathways while promoting extracellular matrix remodeling and gut tissue healing in colitis-affected dogs.
The research identified sugars and amino acids as key discriminative metabolites that distinguished colitic dogs from healthy controls using Raman spectroscopy analysis.
The Quick Take
- What they studied: Can scientists use a special light-based test to detect ulcerative colitis by looking at chemical markers in blood and tissue?
- Who participated: Laboratory mice with colitis, healthy control mice, and dogs with colitis treated with either a supplement or placebo. Exact participant numbers were not specified in the study.
- Key finding: The Raman spectroscopy test identified colitis in mice with 98% accuracy and could predict which dogs would benefit from a synbiotic supplement treatment.
- What it means for you: This test could eventually help doctors diagnose colitis faster and predict which treatments will work best for individual patients, though more human testing is needed before it becomes available in clinics.
The Research Details
Researchers used an advanced technology called Raman spectroscopy, which shines special light on blood and tissue samples to identify chemical fingerprints. These chemical signatures reveal which molecules are present and in what amounts. The team tested this approach first in mice—some healthy and some with colitis—to see if the test could tell them apart. They then extended the research to dogs with colitis, comparing animals that received a special supplement (containing beneficial bacteria and antibodies) to those that received a placebo (fake treatment). By analyzing the chemical patterns, researchers could identify which dogs had colitis and which ones responded well to the supplement.
The scientists also used another technique called proteomics to study proteins in the samples, which helped confirm their findings. They measured inflammation markers and disease severity to see how well the chemical patterns matched actual disease activity. This two-pronged approach—looking at both metabolites (small chemical molecules) and proteins—gave them confidence in their results.
Current methods to diagnose colitis often require uncomfortable procedures like colonoscopies or invasive biopsies. A simple blood test would be much easier for patients and could be done more frequently to monitor disease progression. This research suggests that metabolic changes in the body reflect disease activity, meaning a blood test could become a non-invasive window into what’s happening in the gut.
The study showed excellent accuracy in mice (98%) but moderate accuracy in dogs (81%), suggesting the test works better in controlled laboratory settings than in real-world animals with varied genetics and diets. The research was published in Analytical Chemistry, a respected peer-reviewed journal. However, this work was conducted in animal models only—human studies are needed before this test can be used in medical clinics. The sample sizes were not explicitly stated, which limits our ability to assess statistical power.
What the Results Show
In mice with colitis, researchers identified 16 specific chemical markers in blood that could distinguish sick animals from healthy ones with 98% accuracy—meaning the test was correct 98 times out of 100. These chemical markers correlated strongly with inflammation levels, disease severity scores, weight loss, and tissue damage observed under a microscope.
When tested in dogs with colitis, the Raman spectroscopy test achieved 81% accuracy in differentiating dogs receiving the synbiotic supplement from those receiving placebo. The key chemical differences involved sugars and amino acids—building blocks of proteins. Dogs treated with the supplement showed different patterns in fats and fatty acids compared to untreated dogs, suggesting the supplement was changing the gut’s chemical environment.
Protein analysis confirmed these findings and revealed that the synbiotic supplement reduced inflammatory pathways (the body’s alarm systems) while promoting healing and repair of the gut lining. In placebo-treated dogs, chemical changes were primarily driven by diet, whereas the supplement created additional beneficial metabolic shifts.
The study found that metabolic changes in the blood reflected what was happening in the colon tissue itself, suggesting a blood test could serve as a reliable indicator of gut health without needing tissue samples. The synbiotic supplement—a combination of beneficial bacteria and antibodies—appeared to work by modifying the gut microbiota’s activity and the body’s lipid (fat) metabolism. The research also showed that different treatment responses could be predicted by baseline metabolic profiles, opening the door to personalized medicine approaches.
Previous research has suggested that metabolic changes occur in colitis, but this study is among the first to use Raman spectroscopy for this purpose. The high accuracy rates (98% in mice) exceed many existing diagnostic approaches. The finding that metabolic profiles predict treatment response aligns with emerging research in precision medicine, where individual patient characteristics guide treatment selection. However, the moderate accuracy in dogs (81%) suggests real-world application will be more challenging than laboratory studies.
This research was conducted only in animal models—mice and dogs—not in humans with colitis. Animal studies don’t always translate to human medicine due to differences in genetics, diet, and disease progression. The study didn’t specify exact sample sizes, making it difficult to assess statistical reliability. The dog study included only two groups (supplement vs. placebo), limiting our understanding of how the test performs across different treatment types. Additionally, the researchers didn’t test whether the blood test could detect early-stage colitis or predict disease flares, which would be crucial for clinical use.
The Bottom Line
This research is promising but preliminary. According to Gram Research analysis, Raman spectroscopy metabolic profiling shows strong potential as a diagnostic tool and treatment predictor, but human clinical trials are essential before recommending it for patient care. Current standard diagnostic methods (colonoscopy, blood tests for inflammatory markers) remain the appropriate approach until this technology is validated in humans.
This research is most relevant to gastroenterologists, colitis patients, and pharmaceutical companies developing new treatments. People with ulcerative colitis or inflammatory bowel disease should be aware of this emerging technology but should continue following their doctor’s current diagnostic recommendations. Researchers in metabolomics and precision medicine will find this work particularly valuable.
If human trials begin soon, this technology could potentially become available in specialized clinics within 5-10 years. More realistic timelines suggest 10-15 years before widespread clinical adoption, as regulatory approval and validation studies typically take considerable time.
Frequently Asked Questions
Can a blood test diagnose ulcerative colitis instead of a colonoscopy?
This research shows promise for a blood-based metabolic test achieving 98% accuracy in mice, but human studies are needed. Current colonoscopy remains the gold standard for colitis diagnosis. Future metabolic testing could potentially complement or reduce the need for invasive procedures, but this is not yet available clinically.
What are metabolic biomarkers and why do they matter for colitis?
Metabolic biomarkers are specific chemicals in blood that reflect disease activity. In colitis, these markers change due to inflammation and altered gut bacteria. Detecting these changes could enable earlier diagnosis and help doctors predict which treatments will work best for individual patients without invasive testing.
How soon will this metabolic blood test be available for colitis patients?
This technology is still in the research phase with only animal studies completed. Human clinical trials would need to occur first, typically taking 5-10 years. Realistic timelines suggest 10-15 years before widespread clinical availability, pending regulatory approval and validation studies.
Can this test predict which colitis treatments will work for me?
The research suggests metabolic profiles may predict treatment response—dogs with certain baseline metabolite patterns responded better to synbiotic supplementation. However, this was only demonstrated in animals. Personalized treatment prediction based on metabolic profiling remains experimental and requires human validation.
What is a synbiotic supplement and did it help the dogs in this study?
A synbiotic combines beneficial bacteria (probiotics) with antibodies (IgY). In this study, synbiotic-treated dogs showed improved metabolic profiles with reduced inflammatory markers and enhanced gut healing compared to placebo. However, this was tested only in dogs and requires human studies for clinical recommendations.
Want to Apply This Research?
- Users could log weekly inflammatory symptom scores (abdominal pain, stool frequency, blood in stool) on a 1-10 scale and track them alongside any dietary changes or supplement use. Once metabolic testing becomes available, users could record test results and correlate them with symptom patterns.
- Users with colitis could use the app to experiment with dietary modifications and supplements (under doctor supervision) while tracking symptom changes. This creates a personalized record that could be shared with healthcare providers and compared against future metabolic test results.
- Establish a baseline symptom profile, then monitor changes weekly. Once metabolic biomarker testing becomes available, users could request periodic testing (perhaps quarterly) and track how metabolic markers correlate with their symptom patterns and treatment responses, building a personalized disease profile over time.
This research describes promising laboratory findings in animal models only and has not been tested in humans with ulcerative colitis. The Raman spectroscopy metabolic profiling test is not currently available for clinical use. Individuals with ulcerative colitis or suspected inflammatory bowel disease should consult with a gastroenterologist for proper diagnosis and treatment using established medical approaches. This article is for informational purposes and should not be considered medical advice or a substitute for professional medical evaluation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.